Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bretylium tosylate: a review.

C K Bryan, M H Darby

    American Journal of Hospital Pharmacy
    |September 1, 1979
    PubMed
    Summary

    Bretylium tosylate is an antiarrhythmic drug for severe ventricular arrhythmias unresponsive to other treatments. It affects heart muscle and nerve transmission but requires careful administration and monitoring due to potential side effects like hypotension.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Acyclovir: evaluation of a new antiviral agent.

    Clinical pharmacy·1982
    Same author

    In vitro and in vivo responses of cytomegalovirus to acyclovir.

    The American journal of medicine·1982
    Same author

    Acyclovir treatment of herpes zoster infections. Use in children undergoing bone marrow transplantation.

    JAMA·1982
    Same author

    Estimating creatinine clearance in children: comparison of three methods.

    American journal of hospital pharmacy·1980
    Same author

    Clotrimazole by thumb.

    The New England journal of medicine·1979
    Same author

    Improved patients compliance through use of a daily drug reminder chart.

    American journal of public health·1977

    Area of Science:

    • Pharmacology
    • Clinical Medicine
    • Cardiology

    Background:

    • Bretylium tosylate is a recently approved antiarrhythmic agent.
    • It is indicated for life-threatening ventricular arrhythmias, including ventricular fibrillation and ventricular tachycardia.
    • These arrhythmias are often refractory to first-line antiarrhythmic therapies.

    Purpose of the Study:

    • To review the chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects, drug interactions, and dosage of bretylium tosylate.
    • To provide a comprehensive overview of this antiarrhythmic agent for healthcare professionals.
    • To highlight key aspects relevant to its clinical application and management.

    Main Methods:

    • Review of existing literature on bretylium tosylate.
    • Analysis of pharmacological and pharmacokinetic data.
    • Compilation of clinical usage, adverse events, and drug interactions.

    Main Results:

    • Bretylium tosylate exhibits a positive inotropic effect on the myocardium and blocks sympathetic nerve transmission.
    • It is administered via intramuscular or intravenous routes due to poor oral absorption.
    • Renal excretion necessitates dosage adjustments in patients with renal disease.
    • Hypotension is a common adverse effect; rapid IV administration can cause nausea/vomiting, and IM injections may lead to muscle tissue damage.
    • Potential drug interactions include potentiation of hypotensive effects by quinidine and procainamide, and aggravation of digitalis-induced arrhythmias.

    Conclusions:

    • Bretylium tosylate is effective for resistant ventricular tachyarrhythmias.
    • Its use requires close clinical monitoring due to its adverse effect profile and drug interactions.
    • Dosage adjustments are critical for patients with impaired renal function.

    Related Experiment Videos